From the Guidelines
The POETS trial is not mentioned in the provided evidence, however, based on the most recent and highest quality study available, the American Society of Hematology 2020 guidelines for management of venous thromboembolism, the focus is on the treatment of deep vein thrombosis and pulmonary embolism. The guidelines suggest offering home treatment over hospital treatment for patients with pulmonary embolism with a low risk for complications 1. Key points to consider in the management of venous thromboembolism include:
- The use of clinical prediction scores, such as the Pulmonary Embolism Severity Index (PESI) or simplified PESI, to select patients at low risk for complications 1
- The importance of clinical judgment in determining the best course of treatment, as clinical prediction scores have limited ability to predict patient outcomes 1
- The consideration of home treatment for patients with low-risk pulmonary embolism, as it may be a safe and effective alternative to hospital treatment 1
- The need for careful selection of patients for home treatment, taking into account factors such as support at home, ability to afford medications, and history of adherence 1. The recommended approach is to offer home treatment to patients with low-risk pulmonary embolism, while ensuring that they have adequate support and resources to manage their condition effectively.
From the Research
Overview of Pulmonary Embolism Outcome Trial
There is no direct information available about the POETS trial (Pulmonary Embolism Outcome Trial) in the provided studies.
Available Information on Pulmonary Embolism
- Pulmonary embolism (PE) is a common cause of illness and death, and its treatment includes anticoagulants and thrombolytic agents 2.
- The management of PE is guided by risk stratification according to early mortality, and lactate levels may be helpful for further risk stratification 3.
- Treatment options for PE include anticoagulation therapy, thrombolytic therapy, and thrombectomy 4, 5.
- The use of non-VKA oral anticoagulants, such as rivaroxaban and apixaban, has been shown to be effective in treating PE, with a reduced risk of major bleeding 4.
Limitations of Available Information
- The provided studies do not mention the POETS trial specifically, and therefore, no information can be gathered about this trial from these sources.